Abstract
EPO’s biosimilars in oncology. After a reminder on general conditions for prescribing EPOs and international recommendations, the more specific prescription of biosimilars, their interchangeability, guidelines, traceability, are considered.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Groopman JE et al (1999) J Natl Cancer Inst 91:1616–1634
Caro JJ et al (2001) Cancer 91:2214–2221
Bohlius J et al (2006) J Natl Cancer Inst 98(10):708–714
Bennett CL et al (2008) JAMA 299(8):914–924
Bohlius J et al (2009) Lancet 373(9674):1532–1542
Newland, Black (2008) Ann Pharmacother 42:1865–1870
Henke et al (2006) J Clin Oncol 24:4708–4713
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer-Verlag France
About this chapter
Cite this chapter
Chouaïd, C. (2013). The Oncologist’s Point of View. In: Prugnaud, JL., Trouvin, JH. (eds) Biosimilars. Springer, Paris. https://doi.org/10.1007/978-2-8178-0336-4_6
Download citation
DOI: https://doi.org/10.1007/978-2-8178-0336-4_6
Published:
Publisher Name: Springer, Paris
Print ISBN: 978-2-8178-0335-7
Online ISBN: 978-2-8178-0336-4
eBook Packages: MedicineMedicine (R0)